Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture

被引:66
作者
Lowe, GDO
机构
[1] Royal Infirm, Div Cardiovasc & Med Sci, Glasgow G31 2ER, Lanark, Scotland
[2] Glasgow Royal Infirm, Haemophilia & Thrombosis Ctr, Glasgow G4 0SF, Lanark, Scotland
关键词
thrombosis; thrombophilias; coagulation; fibrinolysis; D-dimer;
D O I
10.1111/j.1365-2141.2006.06021.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The risk of venous or arterial thrombosis is routinely assessed by clinical variables (risk factors) supplemented by measurement of blood lipids and glucose for arterial thrombotic events. Haematological tests that might play a role in risk prediction include haemostatic variables, haematocrit and inflammatory markers (erythrocyte sedimentation rate, plasma viscosity, white cell count). Recent epidemiological studies of these phenotypes and related genotypes are reviewed. For the risk prediction of first venous thrombosis, screening for thrombophilias in 'high-risk' situations does not appear clinically effective or cost-effective; with the possible exception of women considering oral hormone replacement therapy. General screening after a first venous event to predict recurrence (or risk in asymptomatic relatives) does not appear effective; with the possible exception of D-dimer, which requires further study. For risk prediction of first arterial thrombosis, screening adds little to prediction by current clinical risk scores. Screening of persons after a first arterial event, or with atrial fibrillation (e.g. with D-dimer for stroke prediction), requires further study. In conclusion, haematological tests have very limited roles in the prediction of cardiovascular risk, and should only be used according to evidence-based guidelines. The need for management studies is highlighted.
引用
收藏
页码:232 / 250
页数:19
相关论文
共 218 条
[91]   Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors - British Women's Heart and Health Study [J].
Lawlor, DA ;
Smith, GD ;
Rumley, A ;
Lowe, GDO ;
Ebrahim, S .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (05) :955-963
[92]   Venous thrombotic risk in family members of unselected individuals with factor V Leiden [J].
Lensen, RPM ;
Bertina, RM ;
de Ronde, H ;
Vandenbroucke, JP ;
Rosendaal, FR .
THROMBOSIS AND HAEMOSTASIS, 2000, 83 (06) :817-821
[93]   Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients [J].
Lensen, RPM ;
Rosendaal, FR ;
Koster, T ;
Allaart, CF ;
deRonde, H ;
Vandenbroucke, JP ;
Reitsma, PH ;
Bertina, RM .
BLOOD, 1996, 88 (11) :4205-4208
[94]   Medical progress: The antiphospholipid syndrome. [J].
Levine, JS ;
Branch, DW ;
Rauch, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :752-763
[95]   Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease:: does totality of evidence support causal role for homocysteine and preventive potential of folate? [J].
Lewis, SJ ;
Ebrahim, S ;
Smith, GD .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7524) :1053-1056A
[96]  
Libourel EJ, 2002, HAEMATOLOGICA, V87, P1068
[97]  
Lindahl TL, 1999, THROMB HAEMOSTASIS, V81, P18
[98]  
Lindmarker P, 1999, THROMB HAEMOSTASIS, V81, P684
[99]   PLASMA-FIBRINOGEN AND FIBRIN D-DIMER IN PATIENTS WITH ATRIAL-FIBRILLATION - EFFECTS OF CARDIOVERSION TO SINUS RHYTHM [J].
LIP, GYH ;
RUMLEY, A ;
DUNN, FG ;
LOWE, GDO .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1995, 51 (03) :245-251
[100]  
LIP GYH, 1995, BRIT HEART J, V73, P527